These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38160914)

  • 1. Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets.
    Mushtaq A; Wu P; Naseer MM
    Pharmacol Ther; 2024 Feb; 254():108579. PubMed ID: 38160914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development.
    Peerzada MN; Hamel E; Bai R; Supuran CT; Azam A
    Pharmacol Ther; 2021 Sep; 225():107860. PubMed ID: 33895188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
    Nehra B; Mathew B; Chawla PA
    Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
    Kharb R
    Anticancer Agents Med Chem; 2021; 21(11):1338-1349. PubMed ID: 32560614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
    Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
    Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities.
    Akhtar MJ; Yar MS; Khan AA; Ali Z; Haider MR
    Mini Rev Med Chem; 2017; 17(17):1602-1632. PubMed ID: 27804888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterocyclic Compounds: Importance in Anticancer Drug Discovery.
    Kumar N; Goel N
    Anticancer Agents Med Chem; 2022; 22(19):3196-3207. PubMed ID: 35379130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterocyclic Scaffolds: Centrality in Anticancer Drug Development.
    Ali I; Lone MN; Al-Othman ZA; Al-Warthan A; Sanagi MM
    Curr Drug Targets; 2015; 16(7):711-34. PubMed ID: 25751009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents.
    Sachdeva H; Khaturia S; Saquib M; Khatik N; Khandelwal AR; Meena R; Sharma K
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6438-6467. PubMed ID: 35900713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box.
    Martins P; Jesus J; Santos S; Raposo LR; Roma-Rodrigues C; Baptista PV; Fernandes AR
    Molecules; 2015 Sep; 20(9):16852-91. PubMed ID: 26389876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.
    Kumar L; Verma S; Joshi K; Sharma S
    Crit Rev Ther Drug Carrier Syst; 2023; 40(3):47-94. PubMed ID: 36749083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Review of N-Heterocycles as Cytotoxic Agents.
    Kumar D; Jain SK
    Curr Med Chem; 2016; 23(38):4338-4394. PubMed ID: 27516198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Active Heterocyclic Chalcones: Recent Developments.
    Dandawate P; Ahmed K; Padhye S; Ahmad A; Biersack B
    Anticancer Agents Med Chem; 2021; 21(5):558-566. PubMed ID: 32628595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromones: Privileged scaffold in anticancer drug discovery.
    Patil VM; Masand N; Verma S; Masand V
    Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview.
    Lang DK; Kaur R; Arora R; Saini B; Arora S
    Anticancer Agents Med Chem; 2020; 20(18):2150-2168. PubMed ID: 32628593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic nanocatalysts as multifunctional platforms in cancer therapy through the synthesis of anticancer drugs and facilitated Fenton reaction.
    Khan S; Sharifi M; Hasan A; Attar F; Edis Z; Bai Q; Derakhshankhah H; Falahati M
    J Adv Res; 2021 May; 30():171-184. PubMed ID: 34026294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Most Recent Discoveries in Heterocyclic Nanoformulations for Targeted Anticancer Therapy.
    Bhattacharya S; Patel R; Joshi A
    Mini Rev Med Chem; 2022; 22(13):1735-1751. PubMed ID: 35114919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature.
    Kaur R; Kaur P; Sharma S; Singh G; Mehndiratta S; Bedi PM; Nepali K
    Recent Pat Anticancer Drug Discov; 2015; 10(1):23-71. PubMed ID: 25230072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-heterocyclic carbene metal complexes as bio-organometallic antimicrobial and anticancer drugs.
    Patil SA; Patil SA; Patil R; Keri RS; Budagumpi S; Balakrishna GR; Tacke M
    Future Med Chem; 2015; 7(10):1305-33. PubMed ID: 26144266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.